The strategic Chronic Inflammatory Demyelinating Polyneuropathy Market forecast anticipates substantial growth, projecting the market value to more than double from USD 1.996 billion in 2024 to USD 4.332 billion by 2035. This high expansion is supported by a significant Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period (2025–2035), emphasizing the sector's positive long-term outlook despite the rare nature of the disease.

A key factor underpinning this optimistic Chronic Inflammatory Demyelinating Polyneuropathy Market forecast is the expected introduction of novel therapeutic modalities, particularly biologics and targeted immunosuppressive agents. These innovative treatments aim to offer patients alternatives to traditional IVIg and corticosteroid therapies, potentially reducing the burden of frequent infusions and offering more personalized treatment strategies for those who do not respond optimally to standard care.